Table 3.

Antiviral therapy for patients with chronic hepatitis B at different disease stages, 2010-2018

Disease stages	Year
	2010	2011	2012	2013	2014	2015	2016	2017	2018
Non-cirrhotic CHB
No. of CHB patients annually in care	9,239	22,674	33,003	40,896	46,445	52,787	57,360	62,754	68,130
No. of patients on antiviral therapy	2,817	11,395	17,682	22,218	26,225	29,792	32,948	36,177	39,349
% per 100 non-cirrhotic CHB patients	30•49%	50•26%	53•58%	54•33%	56•46%	56•44%	57•44%	57•65%	57•76%
Cirrhosis
No. of cirrhotic patients annually in care	4,395	8,249	10,912	13,040	14,912	16,719	18,071	20,280	20,578
No. of patients on antiviral therapy	1,431	4,757	7,012	8,773	10,429	11,923	13,152	14,821	15,237
% per 100 cirrhotic patients	32•56%	57•67%	64•26%	67•28%	69•94%	71•31%	72•78%	73•08%	74•05%
HCC
No. of HCC patients annually in care	2,176	3,003	3,655	4,186	4,590	4,846	5,134	4,799	5,787
No. of patients on antiviral therapy	638	1,404	2,104	2,593	3,083	3,371	3,698	3,489	4,322
% per 100 HCC patients	29•32%	46•75%	57•56%	61•94%	67•17%	69•56%	72•03%	72•70%	74•68%

CHB, chronic hepatitis B; HCC, hepatocellular carcinoma